Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Interleukin-20 receptor (IL-20R) is a heterodimeric receptor belonging to the IL-10 receptor family. It exists in two forms, Type I (IL20RA + IL20RB) and Type II (IL22RA1 + IL20RB), and binds to interleukins 19, 20, and 24. Signaling primarily occurs through the JAK-STAT pathway, influencing epithelial cell proliferation, wound healing, inflammation, and other processes. Dysregulation of IL-20R signaling is implicated in diseases like psoriasis, rheumatoid arthritis, atherosclerosis, and cancer.
JAK-STAT pathway modulation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin-20 Receptor (IL-20R).